PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

Yu Wang; Yong-Bo Xiang; Xiao-Wei Chen; Tao Zhang; Jian-Yang Wang; Wen-Yang Liu; Lei Deng; Lu-Hua Wang; Shu-Geng Gao; Nan Bi

doi:10.1186/s40779-025-00679-z

Your Location：

Home >

Browse articles >

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

RESEARCH | Updated：2026-01-29

- PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
- PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer
- “在早期非小细胞肺癌治疗领域，研究人员开发了一种名为PRIME的人工智能辅助模型，该模型整合了临床基因组预测因子，以增强风险预测并指导个性化治疗。该模型优于单一液体活检生物标志物和临床治疗特征，在不同的临床场景中表现出一致的稳健性。”
- Military Medical Research 2025年12卷
- Affiliations：
  
  1.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  2.Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  3.Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China
  4.Key Laboratory of Minimally Invasive Therapy Research for Lung Cancer, Chinese Academy of Medical Sciences, Beijing 100021, China
  5.State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Author bio：
  
  * Shu-Geng Gao gaoshugeng@vip.sina.com
  Nan Bi binan_email@163.com
- Funds：
  
  the National Natural Science Foundation of China(82373216;12405407);the CAMS Innovation Fund for Medical Sciences(2024-I2M-ZD-004);the Special Research Fund for Central Universities, Peking Union Medical College(3332023026)
- DOI：10.1186/s40779-025-00679-z
  中图分类号：
- 收稿：2025-01-26，
  
  录用：2025-11-25，
  
  网络首发：2026-01-06，
  
  纸质出版：2025
- Accepted：
Scan QR Code
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, 等. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025,12.

Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025, 12.
Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, 等. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025,12. DOI： 10.1186/s40779-025-00679-z.

Yu Wang, Yong-Bo Xiang, Xiao-Wei Chen, et al. PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer[J/OL]. Military Medical Research, 2025, 12. DOI： 10.1186/s40779-025-00679-z.

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Enhancing the clinical relevance of haemorrhage prediction models in trauma

Artificial intelligence and machine learning for hemorrhagic trauma care

Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer

Build the virtual cell with artificial intelligence: a perspective for cancer research

开裂预应力混凝土梁的检测、评估和加固

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer

DOI：10.1186/s40779-025-00679-z